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Fluorine-18 ﬂuorodeoxyglucose (18F-FDG) positron emission tomography (PET) imaging demonstrated the change of glucose
consumption of tumor cells, but problems with speciﬁcity and diﬃculties in early detection of tumor response to chemotherapy
have led to the development of new PET tracers. Fluorine-18-ﬂuorothymidine (18F-FLT) images cellular proliferation by entering
the salvage pathway of DNA synthesis. In this study, we evaluate the early response of colon carcinoma to the chemotherapeutic
drug,lipo-Dox,inC26murinecolorectalcarcinoma-bearingmiceby 18F-FDGand 18F-FLT.ThemaleBALB/cmicewerebilaterally
inoculated with 1 × 105 and 1 × 106 C26 tumor cells per ﬂank. Mice were intravenously treated with 10mg/kg lipo-Dox at day
8a f t e r18F-FDG and 18F-FLT imaging. The biodistribution of 18F-FDG and 18F-FLT were followed by the microPET imaging at
day 9. For the quantitative measurement of microPET imaging at day 9, 18F-FLT was superior to 18F-FDG for early detection of
tumorresponsetoLipo-DOXat varioustumorsizes(P<0.05). Thedataofbiodistributionshowed similarresultswith thosefrom
the quantiﬁcation of SUV (standard uptake value) by microPET imaging. The study indicates that 18F-FLT/microPET is a useful
imaging modality for early detection of chemotherapy in the colorectal mouse model.
1.Introduction
18F-ﬂuorodeoxyglucose (18F-FDG) is widely used as a non-
invasive marker in clinical oncology. 18F-FDG, an analog of
glucose, undergoes phosphorylation by hexokinase, cannot
further enter glycolysis, and is then trapped in the cell. 18F-
FDG has high-detection sensitivity, but not speciﬁcity; the
propertyshowedthediﬃcultyofdistinguishingproliferation
tumor cells from inﬂammatory cells, making it less suitable
as a marker for studying drug response [1–3]. Because 18F-
FDGisalsometabolizedinnontumortissues,theresultsmay
be false-positive in inﬂammation or reactive tissue [4, 5].
For these reasons, 18F-FDG is not suitable as a marker for
early response to treatment of cancer. Another approach for
tumor visualization is using radiolabeled nucleosides such as
11C-thymidine. Since 11C-thymidine is rapidly incorporated
into newly synthesized DNA, this radiopharmaceutical can
beusedtoimagecellularproliferation[3].However,thehalf-
life of 11C-thymidine and the poor imaging quality limit its
clinicalapplication.Theselimitationsledtothedevelopment
of analogues that are more resistant to degradation and can
be labeled with radionuclides more conductive to routine
clinical use, such as 18F[ 6].
The trapping of 18F-FLT demonstrated with the uptake
of thymidine analogue after phosphorylation by thymidine
kinase 1 (TK1) in the S phase of cell cycle [7]. Shields et
al. used 18F-FLT for noninvasive PET imaging because 18F-
FLT is an analog of thymidine, and the half-life of 18Fi s
longer than that of 11C[ 8]. 18F-FLT was phosphorylated
and incorporated into DNA, which is equivalent to cell
proliferation. DNA production slows as the cell division
decreases, which is one of the earliest responses to cancer
therapy [6, 9]. Because DNA synthesis associated with cell
proliferation turns oﬀ faster than glucose utilization, 18F-
FLT oﬀers a more rapid measure of response than 18F-
FDG. 18F-FLT has been found to be useful for noninvasively
assessing the proliferation rate of several types of tumor,
such as colorectal, oesophageal, and lung tumor [10–13].2 Journal of Biomedicine and Biotechnology
The 18F-FLT could outperform 18F-FDG for monitoring
the response to cytostatic chemotherapy [9, 14]. Evaluation
of tumor proliferative activity by PET using 18F-FLT is a
potential new procedure to assess the viability of tumors as
well as the early eﬀect of cancer therapy [15]. In addition,
18F-FLT has been used to monitor the early response
of tumor with chemotherapy, radiotherapy, and hormone
therapy [3, 15–18].
Doxorubicin is an anthracycline antibiotic with anti-
neoplastic activity. It is commonly used in treating a wide
range of cancers. Doxorubicin can induce some side eﬀects
including nausea, vomiting, and heart arrhythmias. Lipo-
Dox is a liposome-encapsulated dosage form of doxorubicin.
Its main beneﬁt is reduced cardiotoxicity. Taking the advan-
tage of liposome, lipo-Dox can achieve delivery from the
vessel to the tumor. It makes the lipo-Dox accumulate in
the tumor to increase the curative eﬀect [19]. Our previous
report also proved that lipo-Dox could eﬃciently inhibit
the growth of C26 colorectal tumor in mice [20]. Although
previous studies have demonstrated that 18F-FLT might be
a good alternative for followup of the tumor during/after
(chemo-) radiation [5], the evaluation at various tumor sizes
after chemotherapy by lipo-Dox has not been reported. This
study evaluates the imaging potential of 18F-FDG and 18F-
FLT for early detection of tumor response to lipo-Dox in
C26 colorectal tumor-bearing mice and proves that 18F-FLT
is better than 18F-FDG in the evaluation of tumor response
to chemotherapy.
2.MaterialsandMethods
2.1. Preparation of 18F-FLT. The synthetic method of
18F-FLT in this experiment is based on the method
described by Leyton et al. [2] with the 2,3 -anhydro-5 -
O-(4,4 -dimethoxytrityl)-thymidine precursor (ABX, Rade-
berg, Germany). Fluoride-18 was produced from the 30MeV
cyclotron (EBCO, Vancouver, BC, Canada) by irradiating the
pneumatic liquid target at the Institute of Nuclear Energy
Research (INER) and was puriﬁed by AG1x8 resin (Bio-
Rad, Hercules, Calif, USA) with 3.5mg K2CO3 in 1mL H2O
for elution before radiosynthesis. Radioﬂuoridation of the
precursortookplaceinanautosynthesizer(NuclearInterface
GE, M¨ unster, Germany) at 131◦Ca n d1 5 m i ni nD M S O
with the phase transfer catalyst Kryptoﬁx-222. Deprotection
reaction of the radioﬂuorinated precursor was then achieved
at 50◦C for 2min after adding 1mL, 0.1N NaOH. The crude
product was deionized by passing through an enhanced
alumina-N column (Waters, Milford, Mass, USA) and then
puriﬁed by a C-18 preparative HPLC column (Macherey-
Nagel, D¨ uren, Germany) with a precolumn in front of
it (Macherey-Nagel, D¨ uren, Germany). The ﬁnal product
was sterilized by ﬂowing through a 0.2µmm e m b r a n e
ﬁlter (Millipore, Billerica, Mass, USA). The radiochemical
purity was analyzed by an analytical-grade HPLC system
with a C-18 column (Micro Solv, Eatontown, NJ, USA).
The radiochemical purity was more than 95%, and the
radiochemical yield was between 5 to 10%.
2.2. Cell Culture, Animal Model, and Drug Administration.
The C26, a murine colorectal carcinoma, was obtained from
the Bioresource Collection and Research Center (Taiwan).
C e l l sw e r eg r o w ni na5 %C O 2 incubator at 37◦Ci nR P M I -
1640 medium supplemented with 10% heat-inactivated fetal
bovine serum (all from Life Technologies, Gaithersburg, Md,
USA). For animal inoculation, 6∼8 weeks old male BALB/c
mice were obtained from the National Animal Center of
Taiwan (Taipei, Taiwan) and maintained on a standard
diet (Lab diet; PMI Feeds, St. Louis, Mo, USA) at room
temperature,withfreeaccesstotapwaterintheanimalhouse
of the Institute of Nuclear Energy Research (INER), Taiwan.
The mice were subcutaneously injected with 1 × 105 and
1 × 106 C26 cells in the left and right thigh, respectively, at
day 0. Tumor-bearing mice were intravenously treated with
10mg/kg lipo-Dox (TTY) when the tumor size of 1 × 106
cellsinoculationreached ∼50mm3.Atthesametime,tumor-
bearing mice were randomized into two groups, 18F-FDG
and 18F-FLT. The tumor size and body weight were recorded
twice a week. The animal experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) of
the INER.
2.3. Micropet Imaging and Data Analysis. The preparation
of 18F-FLT and 18F-FDG was synthesized with an automatic
apparatusatINER.MicroPETimagingwasperformedonthe
microPET-R4 system (Concorde Microsystems, Knoxville,
Tenn, USA), which has a ﬁeld of view of 8cm axially by
11cm transaxially and is capable of a spatial resolution of
2.3mm and an absolute sensitivity of 1020cps/µCi in the
middle of the ﬁeld of view. To monitor the progression of
the tumors, microPET scanning was performed with ten
mice (ﬁve mice per each group) on days 4, 8, and 9 after
tumor inoculation. Static microPET images were acquired
60min after i.v. administration of ∼200µCi of 18F-FDG or
18F-FLT to evaluate the capability of radiopharmaceuticals
to diﬀerentiate the tumor uptake subsequent to chemother-
apy. The image list-mode data were reconstructed to one
frame. Fourier rebinning and 2D ﬁltered back-projection
reconstruction using Ramp ﬁlters, with one half of the
Nyquist frequency as the cut-oﬀ frequency, were applied
to all static data. For data analysis, a region of interest
(ROI) was placed on each tumor and muscle along the
spine in the transaxial images, including the entire lesion
volume. The average radioactivity concentration within a
tumor or muscle region was obtained from the average pixel
value within the multiple ROI volumes. AsiPro software
(Concorde Microsystems, Knoxville, Tenn, USA) was used to
view the microPET images and for data analysis. The counts
in each ROI were converted to radioactivity per gram of
tissue (nCi/g), assuming a tissue density of 1g/mL, and then
normalized to a percentage injected dose per gram of tissues
(%ID/g) [21, 22]. The %ID/g was deﬁned as the average
radioactivity concentration in several planes of the tumor or
organs divided by the total injected activity. The standard
uptake value, SUV, was calculated as follows: SUV = (A ×
W)/Ainj, where A is the activity of ROI, W is the bodyJournal of Biomedicine and Biotechnology 3
weight of the mice, and Ainj is the injection dose of the
radiopharmaceutical.
2.4. Biodistribution of 18F-FDG and 18F-FLT. Biodistribution
studies of the 18F-FDG and 18F-FLT were performed in
BALB/c mice bearing C26 tumors. The mice were intra-
venously injected with ∼30µCi of 18F-FLT or 18F-FDG at
days 4, 8, and 9 after inoculation of tumor cells. Five mice
at each time point were euthanized by CO2 administration
60mins after the injection. Blood samples were collected
through cardiac puncture after euthanizing the mice. The
organs of interest were removed, washed, and weighed, and
the radioactivity was measured with a gamma counter (1470
WIZARD Gamma Counter, Wallac, Finland). The standards
(n = 5) were prepared to verify the counting eﬃciency of
the gamma counter for each radiotracer. The %ID/g values
were calculated by comparison with standards representing
the injected dose per animal. Data were expressed as mean ±
standard deviation (n = 5).
2.5. Statistical Method. Unpaired t-tests were performed to
compare the diﬀerences between the data. Diﬀerences were
considered signiﬁcant at the 95% conﬁdence level (P < 0.05).
3. Results
3.1. Longitudinal Tumor Imaging with 18F-FDG or 18F-FLT.
The uptake of 18F-FDG/18F-FLT in the tumor and muscle
wasdeterminedlongitudinallybythemicroPETimagesfrom
day 4 after tumor inoculation, corresponding to day 4,
day 8, and day 9 after inoculation of C26 murine colon
carcinoma cells (Figure 1). At day 8, after the microPET
imaging was obtained, mice were injected with 10mg/kg
lipo-Dox intravenously. The uptake of 18F-FDG in the tumor
increased following the growth of the tumor from day 4 to
day 9 after inoculation of the murine colon carcinoma. For
the uptake of 18F-FLT, the accumulation of 18F-FLT reached a
plateau at day 8 and decreased at day 9, when 10mg/kg lipo-
Dox was administered. 18F-FDG/PET imaging showed high
accumulation in the heart, abdomen, and bladder. The 18F-
FLT/PET imaging showed lower background accumulation
in the heart than 18F-FDG/PET imaging. The accumulations
of 18F-FDG in tumors were 4.05 ± 0.50%ID/g and 4.13 ±
0.49%ID/g at day 8 and day 9 after inoculation of 105 colon
carcinoma cells and in tumors were 4.23 ± 0.41%ID/g and
4.47 ± 0.29%ID/g at day 8 and day 9 after inoculation of
106 colon carcinoma cells. The accumulations of 18F-FLT in
tumors were 1.62±0.11%ID/g and 1.23±0.03%ID/g at day
8 and day 9 after inoculation of 105 colon carcinoma cells
a n di nt u m o r sw e r e2 .04±0.13%ID/g and 1.34±0.03%ID/g
at day 8 and day 9 after inoculation of 106 colon carcinoma
cells. (Figure 2). The uptake of 18F-FLT was signiﬁcantly
decreased at day 9 compared with that at day 8 (P < 0.05).
18F-FDG showed tumor-to-muscle (T/M) ratios were
2.08 and 2.19 at day 8, which did not signiﬁcantly diﬀer from
its T/M ratios 2.08 and 2.27 at day 9 after inoculation of 105
and 106 tumor cells at Day 0, respectively. In contrast, the
T/Mratiosof 18F-FLTwere1.44and1.79atday8,whichwere
both signiﬁcantly diﬀerent from its T/M ratio 1.29 and 1.40
at day 9 (P < 0.05) after inoculation of 105 and 106 tumor
cells at Day 0, respectively. These results demonstrated that
18F-FLT/PET could decrease the radioactivity accumulation
in C26 colon carcinoma-bearing animals.
3.2. Biodistribution of 18F-FLT and 18F-FDG. The biodis-
tribution data of 18F-FLT and 18F - F D Ga td a y4 ,d a y8 ,
and day 9 following tumor inoculation in C26-bearing mice
were shown in Table 1. The results of 18F-FDG showed
signiﬁcantaccumulationinthebrain,redmarrow,heart,and
tumor. The radioactivity of 18F - F D Gi nm o s to r g a n sw a sn o t
signiﬁcantly diﬀerent, whether at day 4, day 8, or day 9. The
T/Mratioof 18F-FDGin105 and106 hadthesameproﬁleand
slightly decreased from day 4 to day 9. The results of 18F-FLT
showed signiﬁcant accumulation in the red marrow, kidney,
bladder,smallintestine,andtumors.Theradioactivityof 18F-
FLT in most organs signiﬁcantly diﬀered at day 4, day 8,
and day 9. The biodistribution data showed that the organs
increased from day 4 to day 8 and decreased from day 8
to day 9 after lipo-Dox treatment. The T/M ratio of 18F-
FLT after 105 and 106 tumor cells inoculated had the same
proﬁle, slightly decreasing from day 4 to day 9. According to
biodistribution of 18F-FLT, there were signiﬁcant diﬀerences
from its T/M ratio at day 8 and day 9, both in 105 (P < 0.05)
and 106 (P < 0.01) tumor cell inoculation. However, it was
not represented in 18F-FDG (Figure 3).
4. Discussion
18F-FLT is trapped within the cytosol after being monophos-
phorylated by TK1, a principal enzyme in the salvage
pathway [7]. The advantages of radiolabeled thymidine are
(1) it can be quickly absorbed by the cell; (2) it is stable
when it is phosphorylated by TK1, (3) it can be incorporated
into the DNA, so it becomes metabolically trapped [12, 23].
The activity of TK1 is known to be high in proliferating
and malignant cells and low or absent in quiescent cells.
The potential of 18F-FLT/PET to measure early cytostasis and
cytotoxicity induced by the chemotherapy drug, cisplatin, in
RIF-1-bearing mice has been assessed [2]. An early response
to therapy using 18F-FLT in gastric cancer has also been
found [24]. It was reported that the surviving fraction of
SCCVII cells determined by clonogenic assay was 80% after
10Gy of irradiation, despite a marked reduction in the 18F-
FLTuptake to the background level at 24h after a single
irradiation session [25]. Murayama et al. also demonstrated
the results supported their interpretation that the reduc-
tion of 18F-FLT uptake represented cells showing biologic
impairment of proliferation by irradiation after 24hr [26].
Dimitrakopoulou-Strauss and Strauss indicated that the role
of 18F-FLT is not to stage a tumor, but to biologically
characterize a tumor process and to assess the potential
impact of 18F-FLT uptake with respect to prognosis and
therapeutic outcome [27]. These results showed that 18F-FLT
could be an index to monitor the proliferation of colorectal
carcinoma after chemotherapy. Earlier information on lack
of chemosensitivity will enable oncologist to stop treatment4 Journal of Biomedicine and Biotechnology
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Figure 1: Coronal microPET image showed the radioactivity of 18F-FDG (a) and 18F-FLT (b) at days 4, 8, and 9 after tumor inoculation.
18F-FLT of microPET imaging were presented less activity of background than 18F-FDG. The tumor-bearing mice were administrated with
Lipo-Dox at day 8 after tumor inoculation. (Arrow indicated the C26 tumor; the right side was 106 tumor cell inoculation, and the left side
was 105 cell inoculation.)
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Figure 2: Longitudinal quantiﬁcation of the progression of tumor growth in various sizes in C26-bearing mice derived from 18F-FDG (a) or
18F-FLT (b) microPET images. The uptakes of SUV in 18F-FLT were signiﬁcantly decreased after lipo-Dox treatment. (mean ± SD, n = 3; ∗P
< 0.05; ∗∗P < 0.01).Journal of Biomedicine and Biotechnology 5
Table 1: Biodistribution of 18F-FDG/18F-FLT after i.v. injection.
FDG FLT
Organ Day 4 Day 8 Day 9 Day 4 Day 8 Day 9
Whole blood 0.39 ±0.01 0.42 ±0.04 0.46 ±0.03 1.04 ± 0.19 0.76 ±0.03 1.24 ±0.20
Brain 6.93 ±0.49 6.70 ±0.60 5.44 ±0.52 0.21 ± 0.03 0.15 ±0.01 0.22 ±0.03
Skin 1.11 ±0.06 1.12 ±0.10 0.79 ±0.17 0.66 ± 0.13 0.55 ±0.04 0.74 ±0.12
Muscle 2.62 ±0.41 2.27 ±0.27 2.78 ±0.64 0.75 ± 0.22 0.68 ±0.08 1.01 ±0.21
Bone 1.71 ±0.23 1.66 ±0.23 1.93 ±0.32 0.93 ± 0.08 0.93 ±0.15 0.50 ±0.06
Red marrow 11.89 ±6.11 8.67 ±0.97 5.54 ±1.00 1.77 ± 0.65 3.01 ±1.08 0.98 ±0.30
Heart 15.55 ±1.33 16.94 ±1.95 20.95 ±2.34 0.80 ± 0.15 0.67 ±0.06 0.96 ±0.18
Lung 2.26 ±0.11 2.46 ±0.21 2.40 ±0.22 0.81 ± 0.15 0.64 ±0.03 0.95 ±0.13
Testis 2.44 ±0.10 2.77 ±0.20 2.23 ±0.18 1.49 ± 0.14 1.25 ±0.09 1.71 ±0.19
Spleen 2.71 ±0.31 3.08 ±0.18 3.38 ±0.16 1.79 ± 0.29 2.26 ±0.23 1.23 ±0.21
Pancreas 1.73 ±0.09 1.83 ±0.13 2.14 ±0.11 0.98 ± 0.19 0.76 ±0.04 1.18 ±0.17
Kidney 2.01 ±0.24 1.33 ±0.15 1.90 ±0.15 2.27 ± 0.29 2.46 ±0.27 3.07 ±0.62
Adrenals 3.87 ±0.67 4.55 ±0.43 4.32 ±0.59 1.44 ± 0.22 2.48 ±0.62 1.69 ±0.44
Liver 0.80 ±0.03 0.96 ±0.05 0.93 ±0.05 1.03 ± 0.16 0.80 ±0.05 1.17 ±0.18
Bladder 2.63 ±0.56 2.13 ±0.32 2.75 ±0.86 3.42 ± 0.33 4.84 ±0.77 3.81 ±0.55
Stomach 3.25 ±0.27 5.07 ±0.47 4.54 ±0.49 0.87 ± 0.13 0.81 ±0.05 1.06 ±0.22
Small intestine 3.04 ±0.28 5.33 ±1.59 3.86 ±0.70 3.19 ± 0.73 3.28 ±0.71 2.31 ±0.25
Large intestine 7.11 ±0.61 7.81 ±0.85 7.29 ±0.73 1.54 ± 0.22 1.76 ±0.40 2.27 ±0.31
105 tumor 4.67 ±1.16 5.30 ±0.62 4.32 ±0.56 1.16 ± 0.40 2.70 ±0.34 2.12 ±0.24
106 tumor 9.03 ±3.58 4.83 ±0.61 3.92 ±0.46 2.38 ± 0.37 3.27 ±0.13 2.09 ±0.20
105 T/M 1.58 2.62 1.98 1.65 4.19∗ 2.38
106 T/M 3.49 2.40 1.81 4.02 5.13∗∗ 2.24
Data were expressed as %ID/g (Mean ± SEM, n = 5) (∗: P < 0.05, signiﬁcantly diﬀerent at day 8 and day 9 in 105 tumor cell inoculation; ∗∗: P < 0.05,
signiﬁcantly diﬀerent at day 8 and day 9 in 106 tumor cell inoculation).
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Figure 3: Tumor-to-muscle ratio of 18F-FLT and 18F-FDG in 105
and 106 tumor cells inoculation obtained from biodistribution.
Therewere signiﬁcant diﬀerences inthedetection ofmicroPET-FLT
between day8andday9. (mean ±SD, n = 5; ∗P <0.05; ∗∗P <0.01).
and prevent undue toxicity associated with treatment, as well
as reduce the cost of treatment.
In this study, we utilized 18F-FDG and 18F-FLT/PET
to monitor the early response after treatment of lipo-Dox
in C26 tumor-bearing mice. 18F-FDG uptake is related to
increased glucose metabolism. Since most cancer cells are
metabolically active but fewer cells are proliferating, a higher
uptake of 18F-FDG than of 18F-FLT in the tumor can be
expected [28]. Although the uptake of 18F-FLT in gastric
cancer was signiﬁcantly lower than that of 18F-FDG, the
18F-FLT/PET showed as high sensitivity as 18F-FDG/PET in
detection of gastric cancer [29]. We tried to monitor the
diﬀerent size of C26 tumor model which was designed for
early detection. In the study, we tried to image the microPET
images 4 days after tumor inoculation, when the tumor
could not be observed. Unfortunately, this information also
could not be obtained clearly from the microPET imaging,
regardless of whether 18F-FLT or 18F-FDG/PET was used.
We determined the day for chemotherapy to be 8 days after
tumorinoculation.Becausetherearemanystudiesindicating
when the tumor size is <100mm3, better therapeutic eﬃcacy
can be expected. In the present study, no signiﬁcant changes
in tumor size measured by caliper after 2 ∼ 3d a y so f
lipo-Dox treatment. However, 18F-FLT/PET can detect the
regression of tumor after 24hr of lipo-Dox treatment. 18F-
FLT is superior to 18F-FDG in detecting the change in
tumor size (Figure 2). Biodistribution data also showed6 Journal of Biomedicine and Biotechnology
the similar proﬁle (Table 1). The tumor-to-muscle ratio
identiﬁed signiﬁcant diﬀerence by 18F-FLT in 106 tumors
(P = 0.008; P < 0.01). 18F-FLT/PET correlated well with
cellular proliferation makers in both primary and metastasis
colorectal cancer has been reported [10].
The uptake of 18F-FLT can be an index for cellular
proliferation.PETimagingpermitstheevaluationofatumor
in its entirety, overcoming issues of heterogeneity and tumor
sampling errors and can easily be reported at any point
during treatment [28]. PET imaging is the most promising
techniqueforearly response monitoring, andmanypotential
selective (e.g., 18F-FLT) and less selective (e.g., 18F-FDG)
PET tracers are available [14]. Therefore, 18F-FLT/PET is a
potential tool for noninvasive in vivo assessment for early
response after therapy. 18F-FLT showed decreased uptake
with lipo-Dox treatment, suggesting that this new tracer
may play a role in improving the diagnostic speciﬁcity of
PET. This study showed that 18F-FLT/PET was superior
to 18F-FDG/PET in distinguishing the early response of
Lipo-Dox in the C26 tumor. We provided the tool of 18F-
FLT/PET as a proliferation index in C26-bearing mice.
In conclusions, we suggest that 18F-FLT might be a good
alternative for followup of the tumor after chemotherapy.
This study demonstrated that 18F-FLT is a sensitive tracer
for the imaging of proliferation in tumors and is also a good
tracer to detect early response to chemotherapy treatment.
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